Dual Inhibitors Of Met And Vegf For The Treatment Of Castration- Resistant Prostate Cancer And Osteoblastic Bone Metastases

Patent No. EP2621481 (titled "Dual Inhibitors Of Met And Vegf For The Treatment Of Castration- Resistant Prostate Cancer And Osteoblastic Bone Metastases") was filed by Exelixis on Sep 26, 2011. The application was issued on Oct 19, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
TEVA PHARMACEUTICALSMay 12, 2020LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2621481

EXELIXIS
Application Number
EP11764655A
Filing Date
Sep 26, 2011
Status
Patent Maintained As Amended
Sep 16, 2022
Publication Date
Oct 19, 2022